GlaxoSmithKline is a leading research-based pharmaceutical company, and is the culmination of the merger of two of the industry’s premier companies with years of pioneer studies and breakthroughs.
Its expertise has seen the company become the leading manufacturer of products in the four major therapeutic areas of anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal / metabolic medication. It is also making vast headway in the increasingly important area of vaccines.
GlaxoSmithKline prides itself as being a leader in research and development particularly in the following fields:
Based on the 2002 annual results, the company recorded sales of £21.2 billion (approx. over RM120 billion).
GSK also invested a total of £2.7 billion (approx. RM16 billion) on R&D giving it a top position within the fields of genomics / genetics and new drug discovery technologies.
Being a leader brings responsibility. GSK cares about the impact that we have on the people and places touched by our aim to improve health and education around the world. Our success as a company enables us to play a broader role in society.
Working locally, GSK has been playing an active part in contributing to the society via its community projects - partnership with the Jabatan Hal Ehwal Orang Asli on the adoption of an aboriginal village, Special Children Society of Ampang, and with the British High Commission in co-funding the Chevening Scholarship for Malaysian students wishing to study in the United Kingdom. GSK is also active in contributing to many other healthcare initiatives and ad hoc humanitarian donations.